Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4A1 | P60842 | 18/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.69 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | RELA | Q04206 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pannellin SCHEMBL29721397 | 1.00 | EIF4A1 (0.69) | EIF4A1CYP3A4HIF1APAX8NFKB1 | |
| Aglafolin SCHEMBL748617 | 0.82 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1APAX8NFKB1 | |
| Aglafolin SCHEMBL20496142 | 0.82 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1APAX8NFKB1 | |
| Aglafolin SCHEMBL18835920 | 0.82 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1APAX8NFKB1 | |
| Aglafolin SCHEMBL31581665 | 0.82 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1APAX8NFKB1 | |
| Aglafolin SCHEMBL29369253 | 0.82 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1APAX8NFKB1 | |
| Aglafolin SCHEMBL752127 | 0.82 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1APAX8NFKB1 | |
| SCHEMBL12455862 | 0.81 | EIF4A1 (0.75) | EIF4A1CYP3A4HIF1APAX8NFKB1 | |
| SCHEMBL12455864 | 0.81 | EIF4A1 (0.75) | EIF4A1CYP3A4HIF1APAX8NFKB1 | |
| SCHEMBL23463149 | 0.80 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1APAX8NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364148-B1 | COMBINATION OF ROCAGLAMIDE AND APOPTOSIS INDUCING SUBSTANCES FOR THE TREATMENT OF CANCER | DKFZ DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2018-07-18 | — | — | EP | disclosed |
| US-20180169123-A1 | COMBINATION THERAPY WITH A FLAVAGLINE AND 2-DEOXYGLUCOSE | UNIV HEIDELBERG RUPRECHT KARLS (DE) | 2018-06-21 | — | — | US | disclosed |
| EP-3313446-A1 | COMBINATION THERAPY WITH A FLAVAGLINE AND 2-DEOXYGLUCOSE | Ruprecht-Karls-Universität Heidelberg (DE) | 2018-05-02 | — | — | EP | disclosed |
| CN-107921139-A | Use flavagline and the combination treatment of 2 deoxyglucoses | 海德堡吕布莱希特-卡尔斯大学 | 2018-04-17 | — | — | CN | disclosed |
| US-20160374983-A1 | COMBINATION OF ROCAGLAMIDE AND APOPTOSIS INDUCING SUBSTANCES FOR THE TREATMENT OF CANCER | LI-WEBER MIN (DE) | 2016-12-29 | — | — | US | disclosed |
| WO-2016207363-A1 | COMBINATION THERAPY WITH A FLAVAGLINE AND 2-DEOXYGLUCOSE | Ruprecht-Karls-Universität Heidelberg (DE) | 2016-12-29 | — | — | WO | disclosed |
| US-20160287553-A1 | TRANSLATION INHIBITORS IN HIGH-DOSE CHEMO- AND/OR HIGH-DOSE RADIOTHERAPY | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2016-10-06 | — | — | US | disclosed |
| EP-3071234-A1 | TRANSLATION INHIBITORS IN HIGH-DOSE CHEMO- AND/OR HIGH-DOSE RADIOTHERAPY | Deutsches Krebsforschungszentrum (DE) | 2016-09-28 | — | — | EP | disclosed |
| US-9387192-B2 | Combination of rocaglamide and apoptosis inducing substances for the treatment of cancer | DKFZ DEUTCHERS KREBSFORSCHUNGSZENTRUM (DE) | 2016-07-12 | — | — | US | disclosed |
| US-20160158189-A1 | SENSITIZATION OF CANCER CELLS TO APOPTOSIS INDUCTION BY FLAVAGLINES AND 5-HYDROXY-FLAVONES | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2016-06-09 | — | — | US | disclosed |
| EP-3021842-A1 | SENSITIZATION OF CANCER CELLS TO APOPTOSIS INDUCTION BY FLAVAGLINES AND 5-HYDROXY-FLAVONES | Deutsches Krebsforschungszentrum (DE) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015075165-A1 | TRANSLATION INHIBITORS IN HIGH-DOSE CHEMO- AND/OR HIGH-DOSE RADIOTHERAPY | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2015-05-28 | — | — | WO | disclosed |
| WO-2015007714-A1 | SENSITIZATION OF CANCER CELLS TO APOPTOSIS INDUCTION BY FLAVAGLINES AND 5-HYDROXY-FLAVONES | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2015-01-22 | — | — | WO | disclosed |
| US-20110250166-A1 | COMBINATION OF ROCAGLAMIDE AND APOPTOSIS INDUCING SUBSTANCES FOR THE TREATMENT OF CANCER | DKFZ DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2011-10-13 | — | — | US | disclosed |
| EP-2364148-A1 | COMBINATION OF ROCAGLAMIDE AND APOPTOSIS INDUCING SUBSTANCES FOR THE TREATMENT OF CANCER | DKFZ Deutsches Krebsforschungszentrum (DE) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010057981-A1 | COMBINATION OF ROCAGLAMIDE AND APOPTOSIS INDUCING SUBSTANCES FOR THE TREATMENT OF CANCER | DKFZ DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2010-05-27 | — | — | WO | disclosed |
| EP-2189158-A1 | Combination of rocaglamide and apoptosis inducing substances for the treatment of cancer | DKFZ Deutsches Krebsforschungszentrum, Stiftung des Öffentlichen Rechts (DE) | 2010-05-26 | — | — | EP | disclosed |
| EP-1693059-A1 | Use of rocaglamide derivatives as NF-AT-specific inhibitors for the treatment of certain inflammatory diseases | Deutsches Krebsforschungszentrum (DE) | 2006-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110250166-A1 | COMBINATION OF ROCAGLAMIDE AND APOPTOSIS INDUCING SUBSTANCES FOR THE TREATMENT OF CANCER | BAD, BID, CASP2 | EIF4A1 2331/4885CYP3A4 1164/4885HIF1A 1393/4885 |
| US-20160287553-A1 | TRANSLATION INHIBITORS IN HIGH-DOSE CHEMO- AND/OR HIGH-DOSE RADIOTHERAPY | EIF4E, EIF4EBP1, EIF5B | EIF4A1 14/4885CYP3A4 4881/4885HIF1A 529/4885 |
| US-20160374983-A1 | COMBINATION OF ROCAGLAMIDE AND APOPTOSIS INDUCING SUBSTANCES FOR THE TREATMENT OF CANCER | BAD, BID, CASP2 | EIF4A1 2331/4885CYP3A4 1164/4885HIF1A 1393/4885 |
| US-20160158189-A1 | SENSITIZATION OF CANCER CELLS TO APOPTOSIS INDUCTION BY FLAVAGLINES AND 5-HYDROXY-FLAVONES | CASP5, API5, BAX | EIF4A1 3549/4885CYP3A4 1471/4885HIF1A 480/4885 |
| US-20180169123-A1 | COMBINATION THERAPY WITH A FLAVAGLINE AND 2-DEOXYGLUCOSE | SLC5A2, SLC5A1, G6PD | EIF4A1 2074/4885CYP3A4 456/4885HIF1A 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.